InterShunt initiates study of device for heart failure treatment
The first procedure in the US using the device was performed at The Christ Hospital Health Network in Ohio.
InterShunt Technologies has initiated the EASE HF2 early feasibility study to assess the InterShunt percutaneous atrial shunt catheter (PAS-C) system, intended to alleviate symptoms of heart failure and enhance the quality of life for patients.
The first procedure in the US using the device was performed at The Christ Hospital Health Network in Cincinnati, Ohio, by Dr Sitaramesh Emani and the Structural Heart Intervention Team.
With plans to enrol 20 subjects across up to six US cities, the study targets individuals with heart failure with reduced ejection fraction (HFrEF), which is a condition characterised by the heart’s inability to pump effectively.
